Product Details:

Brand Name: Vonseca


Each Vonseca tablet contains: 


Therapeutic Indications                 

  • Treatment of gastroesophageal reflux disease
  • Treatment of Helicobacter pylori infection                                                        

Dosage and Administration   

  • Reflux oesophagitis
    • Adult: 20 mg once daily for 4 weeks, may be followed by a further 4 weeks if necessary. Maintenance therapy of healing in patients with repeat recurrence or relapse: 10 mg once daily, may be increased to 20 mg once daily if needed.
  • Gastric ulcer
    • Adult: 20 mg once daily for 8 weeks.
  • Prophylaxis of NSAID-induced ulcers
    • Adult: Including cases that occur during low-dose aspirin therapy: 10 mg once daily.
  • Duodenal ulcer
    • Adult: 20 mg once daily for 6 weeks.
  • Eradication of H. pylori associated with peptic ulcer disease
    • Adult: Adjunct in the triple therapy regimen with antibiotics: 20 mg bid for 7 days in combination with amoxicillin and clarithromycin. Alternatively, 20 mg bid may be given for 7 days in combination with amoxicillin and metronidazole.  


  • Lactation. 
  • Concomitant use with atazanavir and rilpivirine                                                           

Warnings and precautions            

  • May mask symptoms of gastric malignancy. 
  • Renal and hepatic impairment. 
  • Pregnancy                                                          

Undesirable Effects        

  • Significant: Clostridium difficile-associated infection, pseudomembranous colitis, increased intragastric pH, benign gastric polyps (prolonged use); increased risk of hip, spine, or wrist osteoporosis-related fractures (long-term use or high doses); hepatic function abnormalities, including liver injury. Rarely, hypomagnesaemia (prolonged use).
  • Gastrointestinal disorders: Diarrhea, constipation, nausea, abdominal distention or discomfort, stomatitis, taste abnormality.
  • Hepatobiliary disorders: Jaundice.
  • Immune system disorders: Hypersensitivity reactions (e.g. urticaria, anaphylactic shock).
  • Investigations: Increased AST, ALT, and gamma-glutamyl transferase.
  • Skin and subcutaneous tissue disorders: Rash, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug eruption                                                             

Pharmacological Properties        

     Vonoprazan is a potassium-competitive acid blocker (PCAB). It competitively inhibits the binding of K ions to hydrogen/potassium-adenosine triphosphate (H+/K+-ATPase) enzyme system that acts as the proton pump of the gastric parietal cell, thereby inhibiting gastric acid production belong to the proton pump inhibitor group is a medication which reduces stomach acid                                                              


   Vonseca  Tablet: Box containing 2 blisters of 10 tablets each